Autopsy report · NCT05828303

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

“Insufficient enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Turning Point Therapeutics, Inc.

Sponsor type

Industry

Conditions

Advanced Solid Tumor; Metastatic Solid Tumor

Interventions

TPX-0005; Metformin Hydrochloride; Digoxin; Rosuvastatin Calcium

Participants

0

Sites

33

Countries

Australia, Brazil, France, Italy, Spain, United States

Trials that died the same way

• Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
  “Insufficient enrollment rate” (91% match in meaning)
• Treatment Prior to Injection and Biopsy of the Vulva
  “Not enough enrollment” (91% match in meaning)
• Family Nurture Intervention in the CHoNJ NICU
  “insufficient enrollment numbers” (91% match in meaning)
• Development of Auditory Skills in Young Deaf Children With Bilateral Cochlear Implants
  “Not sufficient enrollment” (89% match in meaning)
• Guided Imagery and Transcranial Direct Current Stimulation (tDCS) in Women With Chronic Pelvic Pain
  “Lack of enrollment” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.